Document is current
Any future updates will be listed below
-
Authors
Li, Zheqi
McGinn, Olivia
Wu, Yang
Bahreini, Amir
Priedigkeit, Nolan M.
Ding, Kai
Onkar, Sayali
Lampenfeld, Caleb
Sartorius, Carol A.
Miller, Lori
Rosenzweig, Margaret
Cohen, Ofir
Wagle, Nikhil https://orcid.org/0000-0003-3332-9438
Richer, Jennifer K.
Muller, William J. https://orcid.org/0000-0002-7293-4166
Buluwela, Laki https://orcid.org/0000-0001-6973-334X
Ali, Simak https://orcid.org/0000-0002-1320-0816
Bruno, Tullia C. https://orcid.org/0000-0002-6433-0207
Vignali, Dario A. A. https://orcid.org/0000-0002-2771-5992
Fang, Yusi
Zhu, Li
Tseng, George C.
Gertz, Jason
Atkinson, Jennifer M. https://orcid.org/0000-0001-5164-5114
Lee, Adrian V. https://orcid.org/0000-0001-9917-514X
Oesterreich, Steffi https://orcid.org/0000-0002-2537-6923
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA221303)
U.S. Department of Defense (W81XWH1910499)
- License Information
-
More Information
Article History
Received: 30 December 2020
Accepted: 15 March 2022
First Online: 19 April 2022
Competing interests
: S.Oe and A.V.L. receive research support from AstraZeneca PLC. A.V.L. is employee and consultant with UPMC Enterprises, and member of the Scientific Advisory Board, Stockholder and receives compensation from Ocean Genomics. Tsinghua University paid the stipend of University of Pittsburgh-affiliated foreign scholar Yang Wu from Tsinghua University. D.A.A.V. is cofounder and stock holder of Novasenta, Potenza, Tizona, Trishula; stock holder of Oncorus, Werewolf, Apeximmune; patents licensed and royalties of Astellas, BMS, Novasenta; scientific advisory board member—Tizona, Werewolf, F-Star, Bicara, Apeximmune; consultant of Astellas, BMS, Almirall, Incyte, G1 Therapeutics; research funding of BMS, Astellas, and Novasenta. The remaining authors declare no competing financial interests.
